Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours · Estimated delivery Sep 11 - Sep 16
D 74 , 531544 (2018)
Preclinical studies demonstrated that AOD-9604 was generally safe after chronic oral application in rats and cynomolgus monkeys, with no genotoxic concerns identified
They also reported improved knee function, with a 12-point gain in mobility scores versus a 6.5-point increase in the placebo group
However, a number of case reports and analysis of adverse effect databases raised the possibility that the drugs increase the incidence of acute pancreatitis
In May, Novo Nordisk agreed a partnership deal with Septerna to jointly discover and develop multiple oral small molecule obesity and cardiometabolic disease drugs
-1775582746855.png&w=384&q=75)
US$ 25.06
US$ 28.66
US$ 25.09
